Quest PharmaTech, a pharmaceutical company developing and commercializing cancer treatment products, has entered into a relationship with Korean-based AD Biotech to share research and technology development resources to co-develop technologies of both companies.

AD Biotech has provided $2 million of clinical development funding to Quest and will provide up to $10 million for common shares and future revenue sharing. The deal enables Quest to fund its clinical development programs (including those for its newly acquired IgE technology) and gives Quest access to AD Biotech's antibody, protein transduction domain and manufacturing technologies.